NYSEAMERICAN:DXRDaxor Stock Price, Forecast & News

$13.76

0.00 (0.00 %)

(As of 05/27/2020 12:46 PM ET)

Add

Compare

Today's Range

$13.76

Now: $13.76▼

$13.76

50-Day Range N/A

52-Week Range

$7.13

Now: $13.76▼

$17.90

Volume119 shs

Average Volume19,974 shs

Market Capitalization$51.54 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Daxor has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $20.00, Daxor has a potential upside of 45.4% from its current price of $13.76.
Amount of Analyst Coverage
Daxor has received no research coverage in the past 90 days.

2.6 Community Rank

Outperform Votes
Daxor has received 151 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Daxor has received 139 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Daxor has received 52.07% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Daxor and other stocks. Vote “Outperform” if you believe DXR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DXR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Daxor does not currently pay a dividend.
Dividend Growth
Daxor does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Daxor insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Overall Beat the Market Rank^™

1.17 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN

Industry Medical Instruments & Supplies

Sub-IndustryN/A

SectorMedical

Current SymbolNYSEAMERICAN:DXR

Previous SymbolNYSE:DXR

CUSIPN/A

CIK27367

Webwww.daxor.com

Phone+1-212-3308500

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

EmployeesN/A

Outstanding Shares3,747,000

Market Cap$51.54 million

Next Earnings DateN/A

OptionableNot Optionable

Receive DXR News and Ratings via Email

Sign-up to receive the latest news and ratings for DXR and its competitors with MarketBeat's FREE daily newsletter.

Daxor (NYSEAMERICAN:DXR) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Daxor?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Daxor in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Daxor.

What price target have analysts set for DXR?

2 equities research analysts have issued 12-month target prices for Daxor's stock. Their forecasts range from $18.00 to $22.00. On average, they anticipate Daxor's share price to reach $20.00 in the next twelve months. This suggests a possible upside of 45.4% from the stock's current price. View analysts' price targets for Daxor.

Has Daxor been receiving favorable news coverage?

Media coverage about DXR stock has been trending somewhat positive on Wednesday, InfoTrie Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Daxor earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutDaxor.

Are investors shorting Daxor?

Daxor saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 29,200 shares, a drop of 20.4% from the April 15th total of 36,700 shares. Based on an average daily trading volume, of 28,100 shares, the short-interest ratio is presently 1.0 days. Approximately 3.6% of the company's stock are short sold. View Daxor's Current Options Chain.

Who are some of Daxor's key competitors?

Some companies that are related to Daxor include Bovie Medical (BVX), Tristel (TSTL), CRH Medical (CRH), Retractable Technologies (RVP), CRH Medical (CRHM), CRH Medical (CRHM), SDI (SDI), Milestone Scientific (MLSS), Omega Diagnostics Group (ODX), IsoRay (ISR), IsoRay (ISR), TSO3 (TOS), Impression Healthcare (IHL), G Medical (GMV) and TransEnterix (TRXC). View all competitors.

What other stocks do shareholders of Daxor own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Daxor investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Pfizer (PFE), ContraFect (CFRX), Dynavax Technologies (DVAX), Micron Technology (MU), Sanofi (SNY), Verastem (VSTM) and Cidara Therapeutics (CDTX).

Who are Daxor's key executives?

Daxor's management team includes the following people:

Mr. Michael Richard Feldschuh, Chairman, Pres & CEO (Age 50)
Mr. Jonathan Adam Feldschuh, Chief Scientific Officer & Director (Age 54)
Mr. Robert J. Michel CPA, Chief Financial Officer (Age 62)
Ms. Kathryn A. Kornafel, VP of Marketing & Commercial Devel.
Mr. Guido Manzo, VP of Sales

What is Daxor's stock symbol?

Daxor trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "DXR."

Who are Daxor's major shareholders?

Daxor's stock is owned by many different institutional and retail investors. Top institutional shareholders include FNY Investment Advisers LLC (0.27%). Company insiders that own Daxor stock include Edward Feuer, Michael Richard Feldschuh and Robert J Michel. View institutional ownership trends for Daxor.

Which institutional investors are buying Daxor stock?

DXR stock was acquired by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC. Company insiders that have bought Daxor stock in the last two years include Edward Feuer, Michael Richard Feldschuh, and Robert J Michel. View insider buying and selling activity for Daxor.

How do I buy shares of Daxor?

Shares of DXR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Daxor's stock price today?

One share of DXR stock can currently be purchased for approximately $13.76.

How big of a company is Daxor?

Daxor has a market capitalization of $51.54 million.

What is Daxor's official website?

The official website for Daxor is www.daxor.com.

How can I contact Daxor?

Daxor's mailing address is 350 5th Ave Ste 4740, NEW YORK, NY 10118-0002, United States. The company can be reached via phone at +1-212-3308500.

This page was last updated on 5/27/2020 by MarketBeat.com Staff